Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with gene-therapy data can take hours. Ultragenyx Pharmaceutical’s SEC reports dive deep into pivotal-trial outcomes, Orphan Drug milestones, and royalty economics that move RARE’s share price. If you’ve ever scrolled through a 300-page 10-K looking for one clinical-stage update, you know the struggle.
Stock Titan solves that problem. Our AI models read every Ultragenyx quarterly earnings report 10-Q filing, flagging changes in cash runway and R&D spend. The same engine converts a dense 10-K into plain-language highlights, so understanding Ultragenyx SEC documents with AI feels effortless. Real-time alerts surface Ultragenyx Form 4 insider transactions—letting you see when executives adjust positions before key data readouts—while 8-K material events explained by the platform keep you ahead of trial announcements.
Need specifics? Explore:
- Ultragenyx insider trading Form 4 transactions and executive stock transactions Form 4 in real time.
- Ultragenyx annual report 10-K simplified with pipeline milestones, manufacturing risk factors, and revenue segmentation.
- Ultragenyx earnings report filing analysis that tracks quarter-over-quarter burn rate.
- Ultragenyx proxy statement executive compensation benchmarks against peer biotechs.
- Ultragenyx 8-K material events explained—whether it’s FDA feedback or partnership updates.
Every document arrives seconds after EDGAR posts, and AI-powered summaries convert jargon into actionable context. Stop combing through PDFs; start focusing on clinical catalysts, insider sentiment, and the bottom line—all from one streamlined dashboard.
Ultragenyx Pharmaceutical (RARE) reported higher Q3 revenue and a wider loss. Total revenues were $159.9 million, up from $139.5 million a year ago, driven by product sales of $95.0 million and Crysvita royalties of $64.9 million. Crysvita revenue across product sales and royalties reached $111.9 million.
The company posted a net loss of $180.4 million (basic and diluted loss per share $1.81) versus a loss of $133.5 million last year, reflecting increased R&D and SG&A. For the first nine months, revenue was $465.7 million and net loss was $446.4 million.
Cash and cash equivalents were $202.5 million, with $244.8 million of marketable debt securities (current and non‑current). Total assets were $1.19 billion against total liabilities of $1.17 billion, leaving stockholders’ equity at $9.2 million. Liabilities for sales of future royalties totaled $829.3 million. As of October 30, 2025, 96,477,569 shares of common stock were outstanding.
Ultragenyx (RARE) entered a Royalty Purchase Agreement with an OMERS affiliate, receiving
The arrangement ends when OMERS has received 1.55 times the purchase price (
Ultragenyx reported that the first patient has been dosed in the global Aurora study (NCT07157254) evaluating GTX-102 (apazunersen), an investigational antisense oligonucleotide for Angelman syndrome.
Aurora plans to enroll approximately 60 participants ages one to less than 65 across all genotypes in four cohorts. Cohorts A–C are single-arm; Cohort D is randomized 2:1 to GTX-102 or No Treatment, with a 48-week primary efficacy period and crossover at Week 24. Participants may continue in a long-term extension after study completion.
The Phase 3 Aspire study (NCT06617429) is fully enrolled, with 129 participants ages four to 17 with full maternal UBE3A gene deletion randomized across 28 global sites. Data from Aspire are expected in the second half of 2026.
Ultragenyx Pharmaceutical (RARE) insider activity: The company’s Chief Financial Officer reported a sale of common stock on 10/13/2025. The filing shows 7,942 shares were sold at $31.51 per share.
According to the explanation, these shares were sold to pay required tax withholdings related to the vesting of restricted stock units (RSUs). Following the transaction, the reporting person beneficially owned 98,227 shares. The ownership is listed as direct.
The filing notes that the remaining amount includes previously reported shares underlying RSUs that are subject to vesting conditions.
Theodore Alan Huizenga, SVP and Chief Accounting Officer and director of Ultragenyx Pharmaceutical Inc. (RARE), reported a sale of 64 shares of common stock on 09/18/2025 at a price of $29.17 per share. The filing states the shares were sold to pay required tax withholdings related to the vesting of restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 50,242 shares. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
Theodore A. Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc. (RARE), reported a sale of company common stock on 09/05/2025. The Form 4 shows a sale (Code S) of 84 shares at $31.39 per share. After the reported transaction the reporting person beneficially owned 50,306 shares directly. The filing explains the sale represents shares sold to pay required tax withholdings upon vesting of restricted stock units, and also notes the reporting person acquired 266 shares under the company’s Employee Stock Purchase Plan on April 30, 2025. Previously reported RSU-related shares subject to vesting are included in the total.
FAQ
What is the current stock price of Ultragenyx Pharm (RARE)?
What is the market cap of Ultragenyx Pharm (RARE)?
